{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:22:03Z","timestamp":1785129723728,"version":"3.55.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T00:00:00Z","timestamp":1555459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>Single-agent selinexor has limited activity in heavily pretreated patients with metastatic triple-negative breast cancer. Selinexor 60 mg by mouth twice weekly was generally well tolerated with a side-effect profile consistent with previous clinical trials. Future studies of selinexor in this population should focus on combination approaches and a biomarker-driven strategy to identify patients most likely to benefit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This phase II trial evaluated the safety, pharmacodynamics, and efficacy of selinexor (KPT-330), an oral selective inhibitor of nuclear export (SINE) in patients with advanced triple-negative breast cancer (TNBC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This phase II trial was designed to enroll 30 patients with metastatic TNBC. Selinexor was given at 60 mg orally twice weekly on days 1 and 3 of each week, three of each 4-week cycle. The primary objective of this study was to determine the clinical benefit rate (CBR), defined as complete response + partial response + stable disease (SD) \u226512 weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ten patients with a median age of 60 years (range 44\u201371 years) were enrolled between July 2015 and January 2016. The median number of prior chemotherapy lines was 2 (range 1\u20135). A planned interim analysis for the first stage per protocol was performed. Three patients had SD and seven had progressive disease. On the basis of these results and predefined stoppage rules, the study was halted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Selinexor was fairly well tolerated in patients with advanced TNBC but did not result in objective responses. However, clinical benefit rate was 30%, and further investigation of selinexor in this patient population should focus on combination therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0231","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T19:35:42Z","timestamp":1555529742000},"page":"887-e416","source":"Crossref","is-referenced-by-count":42,"title":["A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer"],"prefix":"10.1093","volume":"24","author":[{"given":"Michael","family":"Shafique","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roohi","family":"Ismail-Khan","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Extermann","sequence":"additional","affiliation":[{"name":"Department of Senior Adult Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Goodridge","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boulware","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Hogue","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Khong","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo S.","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,17]]},"reference":[{"key":"2021122507123510000_R1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","article-title":"Nuclear export of proteins and drug resistance in cancer","volume":"83","author":"Turner","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"2021122507123510000_R2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semcancer.2014.03.001","article-title":"Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents","volume":"27","author":"Turner","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"2021122507123510000_R3","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","article-title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","volume":"129","author":"Garzon","year":"2017","journal-title":"Blood"},{"key":"2021122507123510000_R4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/blood.V122.21.90.90","article-title":"Preliminary evidence of anti tumor activity of selinexor (KPT-330) in a phase I trial of a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with relapsed \/ refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL)","volume":"122","author":"Gutierrez","year":"2013","journal-title":"Blood"},{"key":"2021122507123510000_R5","first-page":"1942","article-title":"Anti tumor activity of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) XPO1\/CRM1 antagonist in patients (pts) with relapsed \/ refractory multiple myeloma (MM) Or Waldenstrom's macroglobulinemia (WM)","volume":"122","author":"Chen","year":"2013","journal-title":"Blood"},{"key":"2021122507123510000_R6","author":"U.S. Food and Drug Administration"},{"key":"2021122507123510000_R7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2353\/ajpath.2008.071079","article-title":"Increased survivin expression confers chemoresistance to tumor-associated endothelial cells","volume":"173","author":"Virrey","year":"2008","journal-title":"Am J Pathol"},{"key":"2021122507123510000_R8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/cancers8120111","article-title":"The enrichment of survivin in exosomes from breast cancer cells treated with paclitaxel promotes cell survival and chemoresistance","volume":"8","author":"Kreger","year":"2016","journal-title":"Cancers (Basel)"},{"key":"2021122507123510000_R9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.neo.2015.02.003","article-title":"Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression","volume":"17","author":"Parvani","year":"2015","journal-title":"Neoplasia"},{"key":"2021122507123510000_R10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1535-7163.MCT-13-0416","article-title":"XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer","volume":"13","author":"Cheng","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"2021122507123510000_R11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1186\/s12885-015-1936-z","article-title":"KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models","volume":"15","author":"Gravina","year":"2015","journal-title":"BMC Cancer"},{"key":"2021122507123510000_R12","first-page":"LB","article-title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows enhanced antitumor activity in combination with the PARP inhibitor, olaparib, in models of triple-negative breast cancer","volume":"75","author":"Marijon","year":"2015","journal-title":"Exp Mol Ther"},{"key":"2021122507123510000_R13","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122507123510000_R14","doi-asserted-by":"crossref","first-page":"52935","DOI":"10.18632\/oncotarget.17987","article-title":"Selective inhibitor of nuclear export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3","volume":"8","author":"Soung","year":"2017","journal-title":"Oncotarget"},{"issue":"suppl 6","key":"2021122507123510000_R15","first-page":"383","article-title":"RAS\/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) \u2013 Inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity","volume":"27","author":"Heong","year":"2016","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0231","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/7\/887\/41917936\/oncolo_24_7_887.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/7\/887\/41917936\/oncolo_24_7_887.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:13:42Z","timestamp":1640416422000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/7\/887\/6439244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,17]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,4,17]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0231","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7,1]]},"published":{"date-parts":[[2019,4,17]]}}}